Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H

Slides:

Advertisements

Similar presentations

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Advertisements

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Thomas J. Birdas, MD, Richard P. M

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Survival after Sublobar Resection for Early-Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy Emanuela Taioli, MD, PhD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer Gaurav S. Ajmani, MHS, Chi-Hsiung.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Joshua E. Rosen, BASc, Michelle C

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer Boris Sepesi, MD, Kathryn A. Gold, MD,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer Brian C. Gulack, MD, Chi-Fu Jeffrey Yang,

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

VATS Thymectomy with 3D Vision: A Chance to Further Improve the Outcomes of Thymus Minimally Invasive Surgery Federico Attene, MD, Fabrizio Scognamillo,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer Eric D. Miller, MD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Narcissus, the beam and lung cancer: What is the message?

Treatment Outcomes in Stage I Lung Cancer

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

The Port Site Recurrence after a Thoracoscopic and Video-Assisted Esophagectomy for Advanced Esophageal Cancer Satoshi Yamamoto, PhD, Katsunobu Kawahara,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Marginal pulmonary function should not preclude lobectomy in selected patients with non–small cell lung cancer Matthew D. Taylor, MD, Damien J. LaPar,

Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinoscopy in patients with resected non–small cell lung.

International Thymic Malignancies Interest Group: A Way Forward

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Improved Survival of Stage I Non–Small Cell Lung Cancer: A VA Central Cancer Registry Analysis Matthew J. Boyer, MD, PhD, Christina D. Williams, PhD, MPH, David H. Harpole, MD, Mark W. Onaitis, MD, Michael J. Kelley, MD, Joseph K. Salama, MD Journal of Thoracic Oncology Volume 12, Issue 12, Pages 1814-1823 (December 2017) DOI: 10.1016/j.jtho.2017.09.1952 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Improvement in survival of the radiation cohort with stereotactic body radiation therapy (SBRT) versus with conventionally fractionated radiation (CRT). (A) Four-year OS by year of diagnosis for patients treated with surgery, radiation, or no treatment. Data are mean plus or minus SE. (B) Proportion of patients treated with radiation who underwent CRT and SBRT, by year of diagnosis. (C) Overall survival of all patients undergoing either CRT or SBRT. (D) Lung cancer–specific survival of all patients undergoing either CRT or SBRT. Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Trends in utilization of surgical modalities and associated survival. (A) Proportion of surgical patients undergoing each procedure by the year of diagnosis. (B) Overall survival of surgical patients by modality. (C) Lung cancer–specific survival of surgical patients by modality. (D) Overall status of propensity score–matched surgical patients undergoing video-assisted thoracoscopic surgical (VATS) or open lobectomy. Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Survival after lobectomy is improved over that after sublobar resection for medically fit patients. (A) Overall survival (OS) of propensity score–matched surgical patients undergoing lobectomy or sublobar resection by either a video-assisted thoracoscopic surgical (VATS) or open procedure. (B) Four-year OS after lobectomy or sublobar resection, either VATS or open, for patients with a CCI of 0 or 1. Data are mean plus or minus SE. (C) Four-year OS after lobectomy or sublobar resection, either VATS or open, for patients with a CCI of 2. Data are mean plus or minus SE. Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Survival after lobectomy is superior to stereotactic body radiation therapy (SBRT). (A) Overall survival of all patients undergoing surgery, radiation, or no treatment. (B) Lung cancer–specific survival of all patients undergoing surgery, radiation, or no treatment. (C) Overall survival of propensity score–matched patients treated by either lobectomy or SBRT. (D) Lung cancer–specific survival of propensity score–matched patients treated by either lobectomy or SBRT. Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Tables 1 and 2 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2B Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3B Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3C Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3D Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 4 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 3 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 4 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 5 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 6 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5B Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5C Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5D Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5E Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 7 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 6A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 7A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 7B Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 8 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 8A Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 8B Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Table 9 Journal of Thoracic Oncology 2017 12, 1814-1823DOI: (10.1016/j.jtho.2017.09.1952) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions